Ad Lucem | Jotup

Lucem Health Introduces Reveal for Stroke to Accelerate Treatment of AFib-Related Stroke Risks

Retrieved on:

수요일, 12월 13, 2023

ECG, Risk, Arrhythmia, Ad Lucem, Patient, FDA, Atrial flutter, American Heart Association, Bleeding, Pharmaceutical industry, Stroke, Ventricular fibrillation

DAVIDSON, N.C., Dec. 13, 2023 /PRNewswire/ -- Lucem Health™, a leader in AI-driven early disease detection solutions, announced today the release of Reveal for Stroke, an innovative solution designed to identify patients with undocumented atrial fibrillation (AFib) and higher risk of AFib-related strokes. As noted by the American Heart Association, AFib affects 2.7-6.1 million individuals in the US and significantly increases the risk of ischemic stroke. Thus, the need for early identification and intervention has never been more critical.

Key Points:

However, at least one-in-five AFib cases remain undocumented in clinical practice, leading to many patients missing out on important stroke prevention treatment.
"At Lucem Health, we develop solutions that identify patients with major health risks that are hiding in plain sight.
Lucem Health has partnered with AccurKardia, a renowned ECG-led diagnostics company, to develop Reveal for Stroke.
"Reveal for Stroke represents a shared vision with Lucem Health to harness the full potential of ECG data in managing stroke risks.

Lucem Health Introduces Reveal for Stroke to Accelerate Treatment of AFib-Related Stroke Risks

Retrieved on:

수요일, 12월 13, 2023

ECG, Risk, Arrhythmia, Ad Lucem, Patient, FDA, Atrial flutter, American Heart Association, Bleeding, Pharmaceutical industry, Stroke, Ventricular fibrillation

DAVIDSON, N.C., Dec. 13, 2023 /PRNewswire/ -- Lucem Health™, a leader in AI-driven early disease detection solutions, announced today the release of Reveal for Stroke, an innovative solution designed to identify patients with undocumented atrial fibrillation (AFib) and higher risk of AFib-related strokes. As noted by the American Heart Association, AFib affects 2.7-6.1 million individuals in the US and significantly increases the risk of ischemic stroke. Thus, the need for early identification and intervention has never been more critical.

Key Points:

However, at least one-in-five AFib cases remain undocumented in clinical practice, leading to many patients missing out on important stroke prevention treatment.
"At Lucem Health, we develop solutions that identify patients with major health risks that are hiding in plain sight.
Lucem Health has partnered with AccurKardia, a renowned ECG-led diagnostics company, to develop Reveal for Stroke.
"Reveal for Stroke represents a shared vision with Lucem Health to harness the full potential of ECG data in managing stroke risks.

NuZee Subsidiary Dripkit to Launch Two Single-Serve Pour-Overs for Texas-Based Merit Coffee Co.

Retrieved on:

화요일, 9월 19, 2023

Coffee, Partnership, Ad Lucem

RICHARDSON, Texas, Sept. 19, 2023 /PRNewswire/ -- NuZee, Inc. (Nasdaq: NUZE, $NUZE), a leading coffee co-packing and technology company, today announced its subsidiary, Dripkit, is partnering with Texas-based coffee roaster, Merit Coffee Co., to produce two unique pour-overs. Merit Coffee's top-selling Lucem and Andino Leal will be available in Dripkit's single-serve packaging, and these formats will be launched in mid-November.

Key Points:

RICHARDSON, Texas, Sept. 19, 2023 /PRNewswire/ -- NuZee, Inc. (Nasdaq: NUZE, $NUZE ), a leading coffee co-packing and technology company, today announced its subsidiary, Dripkit, is partnering with Texas-based coffee roaster, Merit Coffee Co., to produce two unique pour-overs.
"We continue to expand the footprint of our Dripkit product and are excited to welcome Merit Coffee to the NuZee family of partners.
"Our coffee drinkers love our farm-to-cup blends, and we are excited that they will be able to drink them in the convenient new Dripkit format," stated Charlie Paulette, Merit Coffee.
Merit Coffee, a premium Texas-based coffee roaster that is turning 15 next year, joins an esteemed line of Dripkit roasting partners.

The Innovation Collaborative™ Sees Double Digit Growth, Invites Digital Health Innovators to Join the Community

Retrieved on:

화요일, 8월 15, 2023

Collaboration, Baylor Research and Innovation Collaborative, Ad Lucem, Science, Patient, Growth, AI, Health, Medical device

DAVIDSON, N.C., Aug. 15, 2023 /PRNewswire/ -- Lucem Health™, a leading provider of transformational clinical AI solutions, announced today that its Innovation Collaborative doubled the number of partners over the past year. A program designed to help get clinical AI/ML innovation to the front lines of healthcare, the Collaborative helps digital health innovators, clinical AI model developers and researchers refine, deploy, and commercialize AI powered solutions. Lucem Health focuses on the practical application of clinical AI, envisioning a world in which clinicians detect problems before they become life threatening and patients get world class care, everywhere.

Key Points:

In the past year, the Innovation Collaborative added digital health and AI/ML innovators such as Digital Diagnostics and Anumana to a group that included Mayo Clinic Platform, Medial EarlySign, Quadrant Health, Centaur Labs, Ground Truth Labs, Cardiologs, and others.
"We're thrilled with the Innovation Collaborative's growth over the past year," said Sean Cassidy, Co-founder and CEO of Lucem Health.
Lucem Health is committed to the growth of the Innovation Collaborative through close partnerships with model developers, researchers, and digital health innovators.
"We invite all AI developers and digital health innovators to join us and become a part of this growing community"
Are you an AI or digital health innovator and are interested in collaborating with kindred spirits?

The Innovation Collaborative™ Sees Double Digit Growth, Invites Digital Health Innovators to Join the Community

Retrieved on:

화요일, 8월 15, 2023

Collaboration, Baylor Research and Innovation Collaborative, Multimedia, Ad Lucem, Science, Patient, Growth, AI, Health, Medical device

DAVIDSON, N.C., Aug. 15, 2023 /PRNewswire/ -- Lucem Health™, a leading provider of transformational clinical AI solutions, announced today that its Innovation Collaborative doubled the number of partners over the past year. A program designed to help get clinical AI/ML innovation to the front lines of healthcare, the Collaborative helps digital health innovators, clinical AI model developers and researchers refine, deploy, and commercialize AI powered solutions. Lucem Health focuses on the practical application of clinical AI, envisioning a world in which clinicians detect problems before they become life threatening and patients get world class care, everywhere.

Key Points:

In the past year, the Innovation Collaborative added digital health and AI/ML innovators such as Digital Diagnostics and Anumana to a group that included Mayo Clinic Platform, Medial EarlySign, Quadrant Health, Centaur Labs, Ground Truth Labs, Cardiologs, and others.
"We're thrilled with the Innovation Collaborative's growth over the past year," said Sean Cassidy, Co-founder and CEO of Lucem Health.
Lucem Health is committed to the growth of the Innovation Collaborative through close partnerships with model developers, researchers, and digital health innovators.
"We invite all AI developers and digital health innovators to join us and become a part of this growing community"
Are you an AI or digital health innovator and are interested in collaborating with kindred spirits?

Lucem Health™ Announces Series A Funding Round

Retrieved on:

화요일, 5월 9, 2023

Mayo Clinic, Marketing, Ad Lucem, Organization, Patient, Physician, Risk, Cassidy, Conditional sentence, AI, Nursing, Medical device

DAVIDSON, N.C., May 9, 2023 /PRNewswire/ -- Lucem Health™, a leading provider of transformational clinical AI technology and solutions, announced today that it has closed a Series A funding round of $7.7 million. Led by Mayo Clinic, Granger Management and Mercy (St Louis), this round builds on Lucem Health's seed funding and includes financing from existing investor Rally Ventures.

Key Points:

DAVIDSON, N.C., May 9, 2023 /PRNewswire/ -- Lucem Health™ , a leading provider of transformational clinical AI technology and solutions, announced today that it has closed a Series A funding round of $7.7 million.
Led by Mayo Clinic, Granger Management and Mercy (St Louis), this round builds on Lucem Health's seed funding and includes financing from existing investor Rally Ventures.
The funding will be used to advance development of Lucem Health's platform for clinical AI solution deployment, grow the company's solution portfolio and expand its sales and marketing capacity.
Lucem Health recently launched Lucem Health Reveal, a family of solutions that identify patients who may be at a higher risk of serious or chronic diseases.

Lucem Health™ Announces Series A Funding Round

Retrieved on:

화요일, 5월 9, 2023

Mayo Clinic, Marketing, Ad Lucem, Organization, Patient, Physician, Risk, Cassidy, Conditional sentence, AI, Nursing, Medical device

DAVIDSON, N.C., May 9, 2023 /PRNewswire/ -- Lucem Health™, a leading provider of transformational clinical AI technology and solutions, announced today that it has closed a Series A funding round of $7.7 million. Led by Mayo Clinic, Granger Management and Mercy (St Louis), this round builds on Lucem Health's seed funding and includes financing from existing investor Rally Ventures.

Key Points:

DAVIDSON, N.C., May 9, 2023 /PRNewswire/ -- Lucem Health™ , a leading provider of transformational clinical AI technology and solutions, announced today that it has closed a Series A funding round of $7.7 million.
Led by Mayo Clinic, Granger Management and Mercy (St Louis), this round builds on Lucem Health's seed funding and includes financing from existing investor Rally Ventures.
The funding will be used to advance development of Lucem Health's platform for clinical AI solution deployment, grow the company's solution portfolio and expand its sales and marketing capacity.
Lucem Health recently launched Lucem Health Reveal, a family of solutions that identify patients who may be at a higher risk of serious or chronic diseases.

New Clinical AI Solutions Enable Early Disease Detection and Proactive Care for Patients with Lower GI Disorders, Diabetes and Prediabetes

Retrieved on:

수요일, 3월 1, 2023

RALEIGH, N.C., March 1, 2023 /PRNewswire/ -- Lucem Health™ today announced the availability of its new early disease detection solutions, Lucem Health Reveal. Lucem Health Reveal leverages existing EHR data to identify patients who may be at a higher risk of serious or chronic disease. Reveal solutions surface previously undiscovered insights in readily available clinical data that can help provider organizations deliver greater clinical value for patients and more financial value to the organization.

Key Points:

– Sean Cassidy, CEO, Lucem Health
Sixty percent of Americans live with at least one serious or chronic disease, such as cancer, diabetes, stroke, or heart disease.
Reveal solutions leverage the promise of AI for early disease detection, and respect clinicians' limited capacity for added clicks, new workload, or administrative burden.
Reveal for Lower GI Disorders - Identifies patients who appear to be at higher risk for colorectal cancer and other serious lower GI disorders.
Reveal for Prediabetes Progression -Identifies patients who appear to be at higher risk of progressing from prediabetes to diabetes within 12 months.

New Clinical AI Solutions Enable Early Disease Detection and Proactive Care for Patients with Lower GI Disorders, Diabetes and Prediabetes

Retrieved on:

수요일, 3월 1, 2023

RALEIGH, N.C., March 1, 2023 /PRNewswire/ -- Lucem Health™ today announced the availability of its new early disease detection solutions, Lucem Health Reveal. Lucem Health Reveal leverages existing EHR data to identify patients who may be at a higher risk of serious or chronic disease. Reveal solutions surface previously undiscovered insights in readily available clinical data that can help provider organizations deliver greater clinical value for patients and more financial value to the organization.

Key Points:

Reveal solutions surface previously undiscovered insights in readily available clinical data that can help provider organizations deliver greater clinical value for patients and more financial value to the organization.
Sixty percent of Americans live with at least one serious or chronic disease, such as cancer, diabetes, stroke, or heart disease.
Reveal solutions leverage the promise of AI for early disease detection, and respect clinicians' limited capacity for added clicks, new workload, or administrative burden.
Reveal for Lower GI Disorders - Identifies patients who appear to be at higher risk for colorectal cancer and other serious lower GI disorders.

CardioWise Joins the Lucem Health Innovation Collaborative as a Founding Member

Retrieved on:

금요일, 6월 10, 2022

FAYETTEVILLE, Ark., June 10, 2022 /PRNewswire-PRWeb/ -- CardioWise® and Lucem Health™ announced that CardioWise has become a founding member of the Lucem Health Innovation Collaborative, a partner program designed to help AI/ML innovation move to the forefront of healthcare. The collaborative launched by Mayo Clinic along with other investing partners will help digital health innovators create, deploy, and commercialize transformational solutions powered by artificial intelligence and machine learning models.

Key Points:

FAYETTEVILLE, Ark., June 10, 2022 /PRNewswire-PRWeb/ -- CardioWise and Lucem Health announced that CardioWise has become a founding member of the Lucem Health Innovation Collaborative, a partner program designed to help AI/ML innovation move to the forefront of healthcare.
"AI has the potential to revolutionize how healthcare is delivered," said Sean Cassidy, CEO, Lucem Health.
Our Innovation Collaborative partners have a "solution first" mindset that considers all the requirements that must be in place for AI to be useful, trusted, and adopted."
Together, Lucem and CardioWise will provide caregivers with next-generation algorithms and data that allows physicians to make better, more informed decisions about their patients' care."